Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatocellular Carcinoma
88%
Tumor
67%
COVID-19
55%
95% Confidence Interval
54%
Influenza Virus
53%
Overall Survival
50%
Multiple Myeloma
43%
Inflammatory Bowel Disease
43%
Virus
39%
In Cancer
39%
Breast Cancer
38%
Liver
35%
Prostate Cancer
33%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
31%
Myelofibrosis
31%
Clinical Trials
30%
United States
30%
Hazard Ratio
29%
Interferon-α (IFN-α)
29%
T Cells
29%
High Risk
29%
Lung Cancer
25%
Chemotherapy
25%
Meta-analysis
25%
Relapsed/refractory multiple Myeloma
25%
Transcription Factor
24%
Odds Ratio
24%
Myeloproliferative Neoplasms
24%
Gene Expression
23%
Fibrosis
22%
Hematopoietic Stem Cells
22%
Dendritic Cells
21%
Liver Transplantation
21%
Progression-free Survival
20%
Crohn's Disease
20%
Phase I Study
20%
Apoptosis
20%
Chronic Graft-versus-host Disease (cGVHD)
19%
Risk Factors
19%
Cancer Cells
18%
Inflammation
18%
Hepatic Stellate Cells
18%
Phosphorylation
18%
Acute Myeloid Leukemia
18%
Lung
18%
Non-muscle Invasive Bladder Cancer (NMIBC)
18%
Lung Cancer Screening
18%
Clinical Outcomes
17%
Ulcerative Colitis
17%
Obesity
17%
Bladder Cancer
17%
Immune Checkpoint Inhibitors
17%
Erythroid
17%
Polycythemia Vera
17%
Tumor Microenvironment
17%
Liver Fibrosis
17%
Tumor Cells
17%
Cirrhosis
17%
Type 2 Diabetes Mellitus (T2DM)
17%
Diabetes
16%
Mouse Model
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Mount Sinai
16%
Phase II Trial
16%
Immune Response
16%
Quality of Life
15%
Graft-versus-host Disease (GvHD)
15%
New York City
15%
Confidence Interval
15%
Radiation Therapy
15%
Resection
15%
Older Adults
14%
Colorectal Cancer
14%
Disease Progression
14%
Myelodysplastic Syndrome
14%
Planar Cell Polarity
13%
Breast Cancer Risk
13%
Signaling Pathway
13%
During Pregnancy
13%
Metastasis
13%
Bone Marrow
13%
Hepatic Stellate Cell Activation
13%
Ruxolitinib
13%
Viral
13%
Innate Immune Response
13%
Transplantation
13%
Patient Outcomes
13%
Adverse Events
13%
Macrophages
13%
Hepatic Fibrosis
13%
Cancer Immunotherapy
13%
Hepatitis C Virus
13%
Human Papillomavirus
13%
Drosophilidae
13%
Malignancy
12%
Therapeutic Potential
12%
Growth Factors
12%
Tumor Protein p53 (TP53)
12%
Chromatin
12%
Leukemia
12%
Medicine and Dentistry
Diseases
100%
Malignant Neoplasm
96%
Hepatocellular Carcinoma
87%
Neoplasm
65%
Overall Survival
55%
Breast Cancer
50%
Multiple Myeloma
48%
Lung Cancer
48%
Chemotherapy
41%
Tumor
39%
Cancer
39%
Magnetic Resonance Imaging
39%
Clinical Trial
35%
Prostate Cancer
35%
COVID-19
35%
Inflammatory Bowel Disease
34%
Biological Marker
34%
Genetics
32%
Radiation Therapy
30%
Recurrent Disease
29%
Transitional Cell Carcinoma
28%
Hazard Ratio
27%
Liver Transplantation
25%
Myelofibrosis
24%
Odds Ratio
23%
Lung
23%
Immunotherapy
22%
Quality of Life
22%
Non Small Cell Lung Cancer
22%
Progression Free Survival
20%
Infection
20%
Adverse Event
20%
Cystectomy
20%
Low Drug Dose
19%
Fibrosis
19%
Cohort Analysis
18%
Crohn's Disease
18%
Bladder Cancer
18%
Human Immunodeficiency Virus
18%
Systematic Review
18%
Diabetes
18%
Lung Cancer Screening
17%
Oncology
17%
Adolescence
17%
Prevalence
17%
Liver Cirrhosis
16%
Computer Assisted Tomography
16%
Colorectal Carcinoma
15%
Liver Disease
15%
Biopsy Technique
15%
Ulcerative Colitis
15%
Health Care Cost
15%
Liver Fibrosis
15%
Myeloproliferative Neoplasm
15%
Meta-Analysis
15%
Arm
15%
Metastatic Carcinoma
15%
Cisplatin
14%
Cancer Therapy
14%
Wart Virus
14%
Immune Checkpoint Inhibitor
13%
Comorbidity
13%
Maturity Onset Diabetes of the Young
12%
Body Mass Index
12%
Inflammation
12%
Oral
12%
Pancreas Cancer
12%
Urothelial Cancer
12%
Cholangiocarcinoma
12%
Pathogenesis
12%
Placebo
12%
Morbidity
11%
Median Follow Up
11%
Colonoscopy
11%
Myelodysplastic Syndrome
11%
Logistic Regression Analysis
11%
Education
11%
Cancer Cell
11%
Liver Cancer
11%
Acute Myeloid Leukemia
11%
Muscle Invasive Bladder Cancer
11%
Proportional Hazards Model
11%
Chemoradiotherapy
10%
Ruxolitinib
10%
Carcinogenesis
10%
Metabolite
10%
Polycythemia vera
10%
Myeloma
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Survival Rate
10%
Hematopoietic Cell
10%
Pediatrics
10%
Hepatectomy
10%
Systemic Therapy
9%
Liver Graft
9%
Nonalcoholic Fatty Liver
9%
Clinician
9%
Cancer Mortality
9%
Hepatic Stellate Cell
9%
Prostatectomy
9%